GORDON, K.; WARREN, R. B.; GOTTLIEB, A. B.; BLAUVELT, A.; THA?I, D.; POULIN, Y.; BOEHNLEIN, M.; BROCK, F.; ARENDT, C.; REICH, K. Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s45, 2020. DOI: 10.25251/skin.4.supp.45. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/994. Acesso em: 3 jul. 2024.